(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688506 · · 12 pages · Chinese
Summary by 6ix AI
The report confirms the accuracy and completeness of the financial information presented, with the board of directors assuming legal responsibility for its content. It highlights significant financial data, including total revenue and net profit attributable to shareholders, along with research and development expenditures. The report also discusses the company's ongoing collaboration with BMS and the achievement of a milestone in a clinical trial, triggering a payment condition.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix
Earlier from Sichuan Biokin Pharmaceutical
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Commitment by the Controlling Shareholder and Actual Controller Not to Reduce Shareholdings in the Company
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Achievement of the Primary Endpoint in the Interim Analysis of the Phase III Clinical Trial of T-Bren (HER2 ADC) for the Treatment of Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer After Failure of Trastuzumab and Taxane Therapy
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Acceptance of the Marketing Application for Izalontamab Brengitecan (iza-bren) for the Second-line Treatment of EGFR-TKI-resistant and EGFR-mutated Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Acceptance of the Marketing Application for iza-bren (Izalontamab Brengitecan, BL-B01D1) for Locally Advanced, Recurrent or Metastatic HR+HER2- Breast Cancer
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Issuance Results of the 1st Tranche of Sci-Tech Innovation Bonds for 2026
Later from Sichuan Biokin Pharmaceutical
All Sichuan Biokin Pharmaceutical news releasesFollow Sichuan Biokin Pharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Biokin Pharmaceutical